Incyte (INCY) Tops Q1 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Incyte (INCY) Tops Q1 EPS by 4c

Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs

May 4, 2021 7:00 AM EDT

 Total product and royalty revenues of $605 million in Q1 2021 (+6% vs Q1 2020) Jakafi® (ruxolitinib) revenues of $466 million in Q1 2021 (+1% vs Q1 2020); reaffirming full year guidance of $2.125-$2.20 billion Pemazyre® (pemigatinib) now also approved in Europe and Japan, becoming the first internally discovered product to be globally commercialized by Incyte Three regulatory submissions accepted by the FDA for Priority Review, including potential approval of ruxolitinib cream in the U.S. for atopic dermatitis in June

Conference Call and Webcast Scheduled Today at... More